|Follow us on:|
Ranbaxy South Africa holds a 68 per cent stake in Sonke Pharmaceuticals, while Community Investment Holdings (CIH) holds the rest.
Sonke Pharmaceuticals won a major tender in 2010 to supply antiretroviral (ARV) drugs for the government hospitals in South Africa.
Ranbaxy USA recently pleaded guilty to three felony counts under the US Federal Food Drug and Cosmetics Act (FDCA), of making sub-standard drugs.
“All Ranbaxy products distributed to the South African public are, and have been, safe, including from the year 2010 and forward,” said Dale Adkisson, executive head of global quality at Ranbaxy, adding that they were in compliance with the terms and conditions of Ranbaxy’s government-approved applications.
Anna Mokgokong, chairwoman of CIH also assured that the drugs made by Sonke Pharmaceuticals in South African markets are safe.
“The US case has absolutely nothing to do with Sonke Pharmaceuticals or any South African operations. Other than this joint venture (with Sonke Pharmaceuticals), CIH has no other relationship with Ranbaxy,” Mokgokong added.